News coverage about MannKind Corporation (NASDAQ:MNKD) has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MannKind Corporation earned a news impact score of 0.16 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.8144000917215 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news stories that may have effected Accern’s analysis:

A number of equities analysts recently commented on the company. Maxim Group reaffirmed a “buy” rating on shares of MannKind Corporation in a report on Friday, September 1st. ValuEngine cut MannKind Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. Zacks Investment Research raised MannKind Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, HC Wainwright assumed coverage on MannKind Corporation in a report on Tuesday, October 10th. They issued a “buy” rating on the stock. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. MannKind Corporation presently has an average rating of “Hold” and an average target price of $0.92.

Shares of MannKind Corporation (NASDAQ:MNKD) traded down $0.02 during trading on Monday, reaching $3.24. The company had a trading volume of 6,259,500 shares, compared to its average volume of 4,129,792. MannKind Corporation has a one year low of $0.67 and a one year high of $6.96. The company has a current ratio of 0.31, a quick ratio of 0.28 and a debt-to-equity ratio of -0.43.

MannKind Corporation (NASDAQ:MNKD) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.11). The business had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.56 million. MannKind Corporation had a negative net margin of 155.83% and a negative return on equity of 24.93%. MannKind Corporation’s revenue was down 98.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.30 earnings per share. analysts forecast that MannKind Corporation will post -1.13 earnings per share for the current year.

In other MannKind Corporation news, Director Kent Kresa purchased 166,600 shares of the firm’s stock in a transaction on Friday, October 13th. The shares were acquired at an average cost of $6.00 per share, with a total value of $999,600.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact MannKind Corporation (MNKD) Share Price” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/11/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-mannkind-corporation-mnkd-share-price.html.

MannKind Corporation Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind Corporation (NASDAQ:MNKD)

Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with MarketBeat.com's FREE daily email newsletter.